Jacobio Pharma receives IND approval for P53 Y220C activator JAB-30300 in US
Overview
Jacobio Pharma, a clinical-stage oncology company committed to developing and providing new and innovative products and solutions to improve people's health, announced it has received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C activator) from the US FDA.
Future plans
Jacobio plans to initiate a phase I/IIa advanced solid tumors clinical trial in the US, to evaluate safety and efficacy of JAB-30300. Jacobio also plans to submit IND in China, and will conduct clinical studies once receives the IND approval.
About P53
- P53 is the single most frequently altered gene in human cancers, with mutations being present in approximately 50% of all invasive tumors.
- JAB-30300 is an orally bioavailable small molecule activator for the treatment of patients with solid tumors harboring P53 Y220C mutation.
- Studies shows that, JAB-30300 has shown very high binding affinity to P53 Y220C mutant proteins.
- Tumor regression was achieved in multiple cancer models covering various tumor types, such as gastric cancer, ovarian cancer, breast cancer and lung cancer.
- The synergistic effect was found when combined with chemo or oncogenic protein inhibitors which indicates a widely combo potential of JAB-30300.
- There is only one P53 Y220C activator program in the phase I clinical stage globally.
- JAB-30300 is expected to be one of the first P53 Y220C activator to be approved.
Jacobio Pharma’s Aim
- Jacobio Pharma’s pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC.
- We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners.
- Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.
